Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OFIX logo OFIX
Upturn stock ratingUpturn stock rating
OFIX logo

Orthofix Medical Inc (OFIX)

Upturn stock ratingUpturn stock rating
$11.16
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/12/2025: OFIX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

5 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $22.3

1 Year Target Price $22.3

Analysts Price Target For last 52 week
$22.3Target price
Low$10.24
Current$11.16
high$20.73

Analysis of Past Performance

Type Stock
Historic Profit -63.49%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 436.87M USD
Price to earnings Ratio -
1Y Target Price 22.3
Price to earnings Ratio -
1Y Target Price 22.3
Volume (30-day avg) 5
Beta 0.81
52 Weeks Range 10.24 - 20.73
Updated Date 07/1/2025
52 Weeks Range 10.24 - 20.73
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.7

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -17.78%
Operating Margin (TTM) -17.64%

Management Effectiveness

Return on Assets (TTM) -5%
Return on Equity (TTM) -27.82%

Valuation

Trailing PE -
Forward PE 20.04
Enterprise Value 572064096
Price to Sales(TTM) 0.54
Enterprise Value 572064096
Price to Sales(TTM) 0.54
Enterprise Value to Revenue 0.71
Enterprise Value to EBITDA 34.53
Shares Outstanding 39180800
Shares Floating 38609185
Shares Outstanding 39180800
Shares Floating 38609185
Percent Insiders 2.79
Percent Institutions 87.84

Analyst Ratings

Rating 3
Target Price 22.3
Buy 1
Strong Buy 2
Buy 1
Strong Buy 2
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Orthofix Medical Inc

stock logo

Company Overview

overview logo History and Background

Orthofix Medical Inc. was founded in 1980. Initially focused on external fixation, the company has grown through acquisitions and product development to offer a wider range of orthopedic and spine solutions. A significant milestone was the merger with SeaSpine in January 2023.

business area logo Core Business Areas

  • Spine Fixation: Develops and markets a comprehensive portfolio of spine fixation products, including thoracolumbar fixation, cervical fixation, interbody implants, and motion preservation systems.
  • Biologics: Offers a range of bone growth stimulation and regenerative solutions, including bone graft substitutes, cellular bone allografts, and growth factors.
  • Orthopedics: Provides orthopedic solutions focused on fracture management, limb reconstruction, and bone regeneration.
  • Bone Growth Therapies: Solutions to help patients heal fractures and stimulate bone growth.

leadership logo Leadership and Structure

The company is led by a board of directors and an executive management team. The organizational structure is typical of a publicly traded medical device company, with functional departments like R&D, marketing, sales, operations, and finance. SerSpine CEO, Keith Valentine, is the CEO of the merged company, and the board is a combination of former Orthofix and SeaSpine board members.

Top Products and Market Share

overview logo Key Offerings

  • M6-C Artificial Cervical Disc: A motion-preserving device for cervical disc replacement. Competitors include Medtronic (MDT) and Johnson & Johnson (JNJ). Market share data is difficult to find for specific products, but the overall cervical disc market is competitive.
  • FORZA XP Expandable Interbody System: An expandable interbody device used in spinal fusion surgeries. Competitors include Stryker (SYK) and NuVasive (NUVA). Again, specific market share data is hard to obtain, but expandable interbody devices are a growing segment.
  • Physiostim: A bone growth stimulator for fracture healing. Market share is estimated at approximately 20% in the bone growth stimulation market. Competitors include DJO Global.

Market Dynamics

industry overview logo Industry Overview

The orthopedic and spine market is a large and growing market driven by an aging population, increasing prevalence of orthopedic conditions, and advancements in technology. The market is competitive, with several large players and smaller specialized companies.

Positioning

Orthofix is positioned as a mid-sized player in the orthopedic and spine market, with a focus on innovation and a comprehensive product portfolio. The merger with SeaSpine aimed to create a stronger, more diversified company.

Total Addressable Market (TAM)

The global orthopedic devices market is estimated to reach over $60 billion by 2028. Orthofix, with projected revenues in the hundreds of millions, has a small but meaningful position in the overall TAM and has opportunity to grow.

Upturn SWOT Analysis

Strengths

  • Comprehensive product portfolio
  • Strong brand reputation
  • Established distribution network
  • Innovative product pipeline
  • Strong leadership team post-merger

Weaknesses

  • Smaller market share compared to larger competitors
  • Integration challenges post-merger
  • Dependence on new product launches
  • Relatively high debt levels

Opportunities

  • Expanding into emerging markets
  • Developing new technologies and products
  • Acquiring complementary businesses
  • Increasing adoption of minimally invasive surgery
  • Capitalizing on the growing aging population

Threats

  • Intense competition
  • Pricing pressures
  • Regulatory changes
  • Product liability claims
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • JNJ
  • SYK
  • NUVA
  • BSX

Competitive Landscape

Orthofix faces competition from larger, more established players in the orthopedic and spine market. The company's competitive advantage lies in its comprehensive product portfolio, focus on innovation, and strong relationships with surgeons. However, the integration post SeaSpine merger is critical.

Major Acquisitions

SeaSpine

  • Year: 2023
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: Merger of equals intended to create a leading global spine and orthopedic company with a more comprehensive product portfolio, expanded distribution network, and enhanced growth opportunities.

Growth Trajectory and Initiatives

Historical Growth: Orthofix has grown organically and through acquisitions. The merger with SeaSpine is expected to accelerate growth.

Future Projections: Analyst estimates vary. Post-merger synergies and new product launches are key drivers for future growth. Look for company guidance post-merger.

Recent Initiatives: The most significant recent initiative is the merger with SeaSpine. Other initiatives may include new product launches, strategic partnerships, and expansion into new markets.

Summary

Orthofix is a mid-sized player in the orthopedic and spine market that completed a merger with SeaSpine. The merger aims to create a larger, more competitive company. Key strengths include a comprehensive product portfolio and innovative pipeline. The company must effectively integrate SeaSpine and address debt to realize the full benefits of the merger.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (10-K, 10-Q)
  • Industry reports
  • Analyst estimates
  • Press releases
  • Company Website

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change. Consult with a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Orthofix Medical Inc

Exchange NASDAQ
Headquaters Lewisville, TX, United States
IPO Launch date 1992-04-24
President, CEO & Director Mr. Massimo Calafiore
Sector Healthcare
Industry Medical Devices
Full time employees 1616
Full time employees 1616

Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and provides 7D flash navigation system for spine and cranial procedures. Its Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.